489478

LSD1 Inhibitor III, CBB1007

The LSD1 Inhibitor III, CBB1007 controls the biological activity of LSD1. This small molecule/inhibitor is primarily used for Cell Structure applications.

• 别名: LSD1 Inhibitor III, CBB1007, LSD Inhibitor III, BHC110 Inhibitor III, Methyl-3-(4-(4-carbamimidoylbenzoyl)piperazine-1-carbonyl)-5-((4-carbamimidoylpiperazin-1-yl)methyl)benzoate, 3TFA, KDM1 Inhibitor III, Histone Lysine Demethylase Inhibitor V, LSD Inhibitor III, Methyl-3-(4-(4-carbamimidoylbenzoyl)piperazine-1-carbonyl)-5-((4-carbamimidoylpiperazin-1-yl)methyl)benzoate, 3TFA, KDM1 Inhibitor III, Histone Lysine Demethylase Inhibitor V, BHC110 Inhibitor III
• 经验公式（希尔记法）: C₂₇H₃₄N₈O₄ · 3C₂HF₃O₂
• CAS号: 1379573-92-8
• 分子量: 876.68
• MDL號碼: MFCD25976706
• 分類程式碼代碼: 12352200

属性

• 品質等級: 100
• 化驗: ≥99% (HPLC)
• 形狀: solid
• 製造商／商標名: Calbiochem^®
• 儲存條件: OK to freeze; desiccated (hygroscopic); protect from light
• 顏色: white
• 溶解度: DMSO: 50 mg/mL
• 運輸包裝: ambient
• 儲存溫度: −20°C
• SMILES 字串: NC(N1CCN(CC2=CC(C(N3CCN(C(C4=CC=C(C(N)=N)C=C4)=O)CC3)=O)=CC(C(OC)=O)=C2)CC1)=N

说明

一般說明

A cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC₅₀ = 5.27 µM for hLSD1) and efficiently blocks LSD1-mediated demethylation of H3K4Me2 and H3K4Me (IC₅₀ ≤ 5 µM) with no effect on H3K4Me3 and H3K9Me2, and LSD2 and JARID1A activities. Increases H3K4Me2 and H3K4Me contents (IC₅₀ ≤ 5 µM), and causes activation of epigenetically suppressed CHRM4/M4-ArchR and SCN3A genes in F9 cells (IC50 ≤ 3.74 µM). Shown to preferentially arrest the growth of pluripotent tumors with minimal effect on non-pluripotent cancer or normal somatic cells (IC₅₀ >100 µM).

Note: the molecular weight is lot-specific and can be found on the vial label.

A cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC₅₀ = 5.27 µM for hLSD1) and efficiently blocks LSD1-mediated demethylation of H3K4Me2 and H3K4Me (IC₅₀ ≤ 5 µM) with no effect on H3K4Me3 and H3K9Me2, and LSD2 and JARID1A activities. Increases H3K4Me2 and H3K4Me contents (IC₅₀ ≤ 5 µM), and causes activation of epigenetically suppressed CHRM4/M4-ArchR and SCN3A genes in F9 cells (IC₅₀ ≤ 3.74 µM). Shown to preferentially arrest the growth of pluripotent tumors with minimal effect on non-pluripotent cancer or normal somatic cells (IC₅₀ >100 µM).

包裝

Packaged under inert gas

警告

Toxicity: Standard Handling (A)

外觀

Supplied as a trifluoroacetate salt.

重構

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

其他說明

Wang, J., et al. 2011. Cancer Res.71, 7238.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

安全信息

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable